|
1
|
Bartosch C, Manuel Lopes J and Oliva E:
Endometrial carcinomas: a review emphasizing overlapping and
distinctive morphological and immunohistochemical features. Adv
Anat Pathol. 18:415–437. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang Q, Jiang X, Li H, et al: Expression
and prognostic value of WISP-1 in patients with endometrial
endometrioid adenocarcinoma. J Obstet Gynaecol Res. 37:606–612.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schouten LJ, Goldbohm RA and van den
Brandt PA: Anthropometry, physical activity, and endometrial cancer
risk: results from the Netherlands cohort study. Int J Gynecol
Cancer. 16(Suppl 2): 4922006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mylonas I: Inhibin-alpha subunit
expression in uterine endometrioid adenocarcinomas and endometrial
cancer cell lines: a potential prognostic factor. Int J Mol Med.
27:309–318. 2011. View Article : Google Scholar
|
|
6
|
Shabani N, Kuhn C, Kunze S, et al:
Prognostic significance of oestrogen receptor alpha (ERalpha) and
beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in
endometrial carcinomas. Eur J Cancer. 43:2434–2444. 2007.
View Article : Google Scholar
|
|
7
|
Lin CH, Chen YC, Chiang CJ, et al: The
emerging epidemic of estrogen-related cancers in young women in a
developing Asian country. Int J Cancer. 130:2629–2637. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kaaks R, Lukanova A and Kurzer MS:
Obesity, endogenous hormones, and endometrial cancer risk: a
synthetic review. Cancer Epidemiol Biomarkers Prev. 11:1531–1543.
2002.PubMed/NCBI
|
|
9
|
Ambros V: microRNAs: tiny regulators with
great potential. Cell. 107:823–826. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chung TK, Cheung TH, Huen NY, et al:
Dysregulated microRNAs and their predicted targets associated with
endometrioid endometrial adenocarcinoma in Hong Kong women. Int J
Cancer. 124:1358–1365. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Torres A, Torres K, Pesci A, et al:
Diagnostic and prognostic significance of miRNA signatures in
tissues and plasma of endometrioid endometrial carcinoma patients.
Int J Cancer. 132:1633–1645. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramón LA, Braza-Boïls A, Gilabert J, et
al: microRNAs related to angiogenesis are dysregulated in
endometrioid endometrial cancer. Hum Reprod. 27:3036–3045.
2012.PubMed/NCBI
|
|
13
|
Li B, Song Y, Liu TJ, et al: miRNA-22
suppresses colon cancer cell migration and invasion by inhibiting
the expression of T-cell lymphoma invasion and metastasis 1 and
matrix metalloproteinases 2 and 9. Oncol Rep. 29:1932–1938.
2013.PubMed/NCBI
|
|
14
|
Wang W, Li F, Zhang Y, Tu Y, Yang Q and
Gao X: Reduced expression of miR-22 in gastric cancer is related to
clinicopathologic characteristics or patient prognosis. Diagn
Pathol. 8:1022013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Franchina T, Amodeo V, Bronte G, et al:
Circulating miR-22, miR-24 and miR-34a as novel predictive
biomarkers to pemetrexed-based chemotherapy in advanced non-small
cell lung cancer. J Cell Physiol. 229:97–99. 2013.PubMed/NCBI
|
|
16
|
Shi TY, Cheng X, Yu KD, et al: Functional
variants in TNFAIP8 associated with cervical cancer susceptibility
and clinical outcomes. Carcinogenesis. 34:770–778. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jiang R, Deng L, Zhao L, et al: miR-22
promotes HBV-related hepatocellular carcinoma development in males.
Clin Cancer Res. 17:5593–5603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patel JB, Appaiah HN, Burnett RM, et al:
Control of EVI-1 oncogene expression in metastatic breast cancer
cells through microRNA miR-22. Oncogene. 30:1290–1301. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pandey DP and Picard D: miR-22 inhibits
estrogen signaling by directly targeting the estrogen receptor
alpha mRNA. Mol Cell Biol. 29:3783–3790. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Merlo S and Sortino MA: Estrogen activates
matrix metalloproteinases-2 and -9 to increase beta amyloid
degradation. Mol Cell Neurosci. 49:423–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shuman Moss LA, Jensen-Taubman S and
Stetler-Stevenson WG: Matrix metalloproteinases: changing roles in
tumor progression and metastasis. Am J Pathol. 181:1895–1899.
2012.PubMed/NCBI
|
|
22
|
Królik M and Milnerowicz H: The effect of
using estrogens in the light of scientific research. Adv Clin Exp
Med. 21:535–543. 2012.PubMed/NCBI
|
|
23
|
Kulie T, Slattengren A, Redmer J, Counts
H, Eglash A and Schrager S: Obesity and women’s health: an
evidence-based review. J Am Board Fam Med. 24:75–85. 2011.
|
|
24
|
Dossus L, Lukanova A, Rinaldi S, et al:
Hormonal, metabolic, and inflammatory profiles and endometrial
cancer risk within the EPIC cohort--a factor analysis. Am J
Epidemiol. 177:787–799. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Knapp P, Chabowski A, Blachnio-Zabielska
A, Walentowicz-Sadłecka M, Grabiec M and Knapp PA: Expression of
estrogen receptors (alpha, beta), cyclooxygenase-2 and aromatase in
normal endometrium and endometrioid cancer of uterus. Adv Med Sci.
58:96–103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shirali S, Aghaei M, Shabani M, Fathi M,
Sohrabi M and Moeinifard M: Adenosine induces cell cycle arrest and
apoptosis via cyclinD1/Cdk4 and Bcl-2/Bax pathways in human ovarian
cancer cell line OVCAR-3. Tumour Biol. 34:1085–1095. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X and Zou S: The relationship of
CyclinD1 and estrogen receptor expression in the process of
proliferation and metastasis in breast neoplasm. J Tongji Med Univ.
21:231–232. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Penttinen P, Jaehrling J, Damdimopoulos
AE, et al: Diet-derived polyphenol metabolite enterolactone is a
tissue-specific estrogen receptor activator. Endocrinology.
148:4875–4886. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen X, Yan Q, Li S, et al: Expression of
the tumor suppressor miR-206 is associated with cellular
proliferative inhibition and impairs invasion in ERalpha-positive
endometrioid adenocarcinoma. Cancer Lett. 314:41–53. 2012.
View Article : Google Scholar
|
|
30
|
Brucka A and Szyłło K: Immunoexpression of
the PTEN protein and matrix metalloproteinase-2 in endometrial
cysts, endometrioid and clear cell ovarian cancer. Ginekol Pol.
84:344–351. 2013.PubMed/NCBI
|
|
31
|
Puljiz M, Puljiz Z, Vucemilo T, et al:
Prognostic significance of matrix metalloproteinases 2 and 9 in
endometrial cancer. Coll Antropol. 36:1367–1372. 2012.PubMed/NCBI
|
